FTO (Q9C0B1) variants and mutations
FTO (also known as Q9C0B1) is a human protein-coding gene encoding an alpha-ketoglutarate-dependent dioxygenase protein. It removes selected methyl modifications from RNA and participates in regulation of energy balance and cellular metabolism. Common intronic variation at the FTO locus has one of the strongest replicated genetic associations with body-mass index and obesity risk. This analysis covers 820 FTO variants and mutations. Of these, 80% have computational variant effect predictions. Disease context includes lethal polymalformative syndrome, Boissel type, obesity disorder, and type 2 diabetes mellitus. Example FTO variants include M1V, K2E, and K2N.
Variant analysis overview
- Gene: FTO
- Protein: Q9C0B1
- UniProt accession: Q9C0B1
- Organism: Homo sapiens
- Variants analyzed: 820
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 558 unspecified-consequence records; 135 missense variants; 107 synonymous variants; 11 frameshift variants; 7 stop-gained variants; 2 splice-region variants
- Prediction scores: 659 variants have prediction scores (80% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: lethal polymalformative syndrome, Boissel type, obesity disorder, type 2 diabetes mellitus, diabetes mellitus, breast carcinoma, hypertensive disorder, atrial fibrillation, heart failure, breast cancer, osteoarthritis, Abnormality of the skeletal system, chronic kidney disease.
Protein structure and variant hotspots
- Protein features: 11 binding sites; 2 post-translational modification sites.
- PTM context: 9 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable FTO variants
Examples include M1V, K2E, K2N, K2Q, K2T, K2R, R3C, R3L. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1V (p.Met1Val), rs534074284, ClinGen CA281381703, ClinVar RCV003143427, MetaLR 0.39, MetaSVM -0.21, Uncertain significance, Lethal polymalformative syndrome, Boissel type
- K2E (p.Lys2Glu), 1000Genomes rs201836578, TOPMed rs201836578, gnomAD rs201836578, REVEL 0.30, CADD 32.00
- K2N (p.Lys2Asn), gnomAD rs989161287, REVEL 0.26, CADD 31.00
- K2Q (p.Lys2Gln), 1000Genomes rs201836578, TOPMed rs201836578, gnomAD rs201836578, REVEL 0.27, CADD 31.00
- K2T (p.Lys2Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K2R (p.Lys2Arg), gnomAD 16-53704189-A-G, REVEL 0.25, CADD 27.10
- R3C (p.Arg3Cys), rs765157936, ClinGen CA8058255, ClinVar RCV002783328, ExAC rs765157936, REVEL 0.38, CADD 29.20, Uncertain significance, Inborn genetic diseases
- R3L (p.Arg3Leu), TOPMed rs1161946063, gnomAD rs1161946063, REVEL 0.32, CADD 31.00, Uncertain significance
- R3P (p.Arg3Pro), rs1161946063, ClinGen CA395927468, ClinVar RCV003679567, TOPMed rs1161946063, REVEL 0.35, CADD 32.00, Uncertain significance, not provided
- R3G (p.Arg3Gly), gnomAD 16-53704191-C-G, REVEL 0.35, CADD 27.80
- R3H (p.Arg3His), gnomAD 16-53704192-G-A, REVEL 0.34, CADD 31.00
- R3R (p.Arg3Arg), rs1598446564, gnomAD 16-53704193-C-T, CADD 13.80
- T4A (p.Thr4Ala), rs752817421, ClinGen CA8058256, ClinVar RCV001877464, ExAC rs752817421, REVEL 0.10, CADD 16.50, Uncertain significance, not provided
- T4I (p.Thr4Ile), gnomAD rs1456216323, REVEL 0.09, CADD 20.40
- T4P (p.Thr4Pro), ExAC rs752817421, TOPMed rs752817421, gnomAD rs752817421, REVEL 0.16, CADD 19.10, Uncertain significance
- T4T (p.Thr4Thr), rs115368866, gnomAD 16-53704196-C-T, CADD 10.80
- P5L (p.Pro5Leu), TOPMed rs1035019229, gnomAD rs1035019229, REVEL 0.17, CADD 14.20
- P5R (p.Pro5Arg), TOPMed rs1035019229, gnomAD rs1035019229, REVEL 0.09, CADD 11.50
- P5S (p.Pro5Ser), Ensembl rs1440570070, REVEL 0.10, CADD 17.40
- P5Q (p.Pro5Gln), gnomAD 16-53704198-C-A, REVEL 0.14, CADD 9.41
- P5P (p.Pro5Pro), gnomAD 16-53704199-G-A, CADD 15.80
- T6A (p.Thr6Ala), TOPMed rs913398301, gnomAD rs913398301, REVEL 0.29, CADD 22.50
- T6I (p.Thr6Ile), 1000Genomes rs546144833, ExAC rs546144833, gnomAD rs546144833, REVEL 0.21, CADD 22.80
- T6S (p.Thr6Ser), TOPMed rs913398301, gnomAD rs913398301
- T6N (p.Thr6Asn), gnomAD 16-53704201-C-A, REVEL 0.19, CADD 17.40
- T6T (p.Thr6Thr), rs73609956, gnomAD 16-53704202-T-C, CADD 10.50
- A7P (p.Ala7Pro), TOPMed rs1971811361
- A7S (p.Ala7Ser), gnomAD 16-53704203-G-T, REVEL 0.13, CADD 17.60
- A7A (p.Ala7Ala), rs1230174514, gnomAD 16-53704205-C-T, CADD 9.65
- A7T (p.Ala7Thr), gnomAD 16-53711437-G-A, CADD 0.64, SIFT 0.32
- A7D (p.Ala7Asp), gnomAD 16-53711438-C-A, CADD 6.75, SIFT 0.03
- A7V (p.Ala7Val), rs2075774724, gnomAD 16-53711438-C-T, CADD 7.99, SIFT 0.02
- E8G (p.Glu8Gly), gnomAD rs1329981588, REVEL 0.33, CADD 24.50
- E8K (p.Glu8Lys), cosmic curated COSV50907, ExAC rs778741837, TOPMed rs778741837, gnomAD rs778741837, REVEL 0.24, CADD 23.80
- E8R (p.Glu8Arg), gnomAD 16-53704203-G-GC, CADD 24.70
- E8* (p.Glu8Ter), gnomAD 16-53704206-G-T, CADD 40.00
- E9* (p.Glu9Ter), Ensembl rs1050722057
- E9Q (p.Glu9Gln), Ensembl rs1050722057
- E9E (p.Glu9Glu), rs781697663, gnomAD 16-53704211-A-G, CADD 13.40
- R10* (p.Arg10Ter), gnomAD rs1282501161
- R10L (p.Arg10Leu), 1000Genomes rs575883122, ExAC rs575883122, TOPMed rs575883122, gnomAD rs575883122, REVEL 0.12, CADD 22.40
- R10Q (p.Arg10Gln), 1000Genomes rs575883122, ExAC rs575883122, TOPMed rs575883122, gnomAD rs575883122, REVEL 0.16, CADD 19.90
- R10G (p.Arg10Gly), gnomAD 16-53704212-C-G, REVEL 0.17, CADD 18.20
- R10R (p.Arg10Arg), gnomAD 16-53704212-C-A, CADD 13.40
- E11D (p.Glu11Asp), TOPMed rs1388384491, gnomAD rs1388384491, REVEL 0.20, CADD 24.40
- E11Q (p.Glu11Gln), gnomAD 16-53704215-G-C, REVEL 0.21, CADD 26.10
- E11G (p.Glu11Gly), gnomAD 16-53704216-A-G, REVEL 0.26, CADD 33.00
- E11A (p.Glu11Ala), gnomAD 16-53704216-A-C, REVEL 0.20, CADD 27.80
- R12G (p.Arg12Gly), TOPMed rs1971815489, Uncertain significance, Inborn genetic diseases
- R12L (p.Arg12Leu), gnomAD 16-53704219-G-T, REVEL 0.26, CADD 32.00
- R12H (p.Arg12His), gnomAD 16-53704219-G-A, REVEL 0.23, CADD 32.00
- E13* (p.Glu13Ter), rs2544857861, ClinVar RCV004585211, CADD 42.00, Uncertain significance
- E13K (p.Glu13Lys), NCI-TCGA TCGA novel, CADD 0.23, Variant assessed as somatic; moderate impact.
- E13Q (p.Glu13Gln), gnomAD 16-53704221-G-C, REVEL 0.23, CADD 25.80
- A14G (p.Ala14Gly), TOPMed rs1768475718, REVEL 0.23, CADD 32.00
- A14T (p.Ala14Thr), TOPMed rs1016221892, gnomAD rs1016221892, REVEL 0.21, CADD 25.60
- K15E (p.Lys15Glu), gnomAD 16-53704227-A-G, REVEL 0.23, CADD 33.00
- K15R (p.Lys15Arg), gnomAD 16-53704228-A-G, REVEL 0.14, CADD 34.00
- K15* (p.Lys15Ter), gnomAD 16-53711452-A-T, CADD 16.70
- K15K (p.Lys15Lys), gnomAD 16-53711454-G-A, CADD 15.80
- K16N (p.Lys16Asn), Ensembl rs1567315554, REVEL 0.24, CADD 24.30
- K16Q (p.Lys16Gln), ExAC rs774232694, TOPMed rs774232694, gnomAD rs774232694, REVEL 0.23, CADD 28.40
- K16R (p.Lys16Arg), gnomAD rs2078482563, REVEL 0.19, CADD 26.10
- K16K (p.Lys16Lys), gnomAD 16-53810142-A-G, CADD 16.20
- L17R (p.Leu17Arg), rs1212496012, gnomAD 16-53711435-T-G, CADD 7.39, SIFT 0.05
- L17L (p.Leu17Leu), gnomAD 16-53711436-G-T, CADD 0.34
- R18G (p.Arg18Gly), gnomAD 16-53810146-A-G, REVEL 0.34, MetaLR 0.14
- R18K (p.Arg18Lys), gnomAD 16-53810147-G-A, REVEL 0.14, MetaLR 0.06
- R18S (p.Arg18Ser), gnomAD 16-53810148-G-C, REVEL 0.29, MetaLR 0.13
- L19I (p.Leu19Ile), gnomAD 16-53810149-C-A, REVEL 0.25, MetaLR 0.45
- L20L (p.Leu20Leu), rs762149812, gnomAD 16-53810154-T-C, CADD 6.62
- E21Q (p.Glu21Gln), Ensembl rs2078482798
- E22E (p.Glu22Glu), gnomAD 16-53810160-G-A, CADD 7.98
- L23P (p.Leu23Pro), Ensembl rs2078482948
- L23V (p.Leu23Val), TOPMed rs1211420864, gnomAD rs1211420864, REVEL 0.20, CADD 18.60
- L23I (p.Leu23Ile), gnomAD 16-53810161-C-A, REVEL 0.09, MetaLR 0.14
- L23R (p.Leu23Arg), gnomAD 16-53810162-T-G, REVEL 0.39, MetaLR 0.38
- E24K (p.Glu24Lys), gnomAD 16-53810164-G-A, REVEL 0.20, MetaLR 0.11
- D25G (p.Asp25Gly), 1000Genomes rs572790599, ExAC rs572790599, gnomAD rs572790599, REVEL 0.33, CADD 24.30
- D25V (p.Asp25Val), gnomAD 16-53810168-A-T, REVEL 0.46, MetaLR 0.29
- D25E (p.Asp25Glu), gnomAD 16-53810169-C-A, REVEL 0.19, MetaLR 0.10
- D25D (p.Asp25Asp), rs750855307, gnomAD 16-53810169-C-T, CADD 7.75
- T26A (p.Thr26Ala), TOPMed rs1294612571, gnomAD rs1294612571, REVEL 0.04, CADD 18.40
- T26I (p.Thr26Ile), ExAC rs756522457, TOPMed rs756522457, gnomAD rs756522457, REVEL 0.22, CADD 20.60
- T26S (p.Thr26Ser), TOPMed rs1294612571, gnomAD rs1294612571, REVEL 0.05, CADD 16.90
- T26P (p.Thr26Pro), gnomAD 16-53810170-A-C, REVEL 0.19, MetaLR 0.11
- T26T (p.Thr26Thr), rs970217524, gnomAD 16-53810172-T-C, CADD 1.99
- W27G (p.Trp27Gly), rs564070241, gnomAD 16-53711449-T-G, CADD 7.04, SIFT 0.33
- W27R (p.Trp27Arg), rs564070241, gnomAD 16-53711449-T-C, CADD 5.94, SIFT 0.34
- W27S (p.Trp27Ser), gnomAD 16-53711450-G-C, CADD 7.55, SIFT 0.40
- W27L (p.Trp27Leu), gnomAD 16-53711450-G-T, CADD 8.13, SIFT 0.64
- W27* (p.Trp27Ter), gnomAD 16-53810175-G-A, CADD 36.00
- L28V (p.Leu28Val), ESP rs149393601, ExAC rs149393601, TOPMed rs149393601
- L28I (p.Leu28Ile), gnomAD 16-53810176-C-A, REVEL 0.21, MetaLR 0.28
- L28L (p.Leu28Leu), rs754399299, gnomAD 16-53810178-C-T, CADD 6.38
- Y30H (p.Tyr30His), rs1275818602, ClinGen CA396120822, ClinVar RCV002785617, ClinVar RCV004973614, REVEL 0.66, CADD 26.00, Uncertain significance, Inborn genetic diseases; not provided
- L31V (p.Leu31Val), NCI-TCGA Cosmic COSV1011, cosmic curated COSV10115, NCI-TCGA Cosmic COSV6711, Variant assessed as somatic; moderate impact.
- T32A (p.Thr32Ala), ESP rs373028121, ExAC rs373028121, TOPMed rs373028121, gnomAD rs373028121, REVEL 0.16, CADD 22.10, Uncertain significance
- T32I (p.Thr32Ile), TOPMed rs1194621251, gnomAD rs1194621251, REVEL 0.32, CADD 24.30
- T32S (p.Thr32Ser), ESP rs373028121, ExAC rs373028121, TOPMed rs373028121, gnomAD rs373028121, REVEL 0.17, CADD 20.10, Uncertain significance, Inborn genetic diseases
- T32N (p.Thr32Asn), gnomAD 16-53810189-C-A, REVEL 0.14, MetaLR 0.27
- T32T (p.Thr32Thr), rs890975683, gnomAD 16-53810190-C-T, CADD 5.19
- P33T (p.Pro33Thr), gnomAD rs1292607982, REVEL 0.55, CADD 23.90
- P33L (p.Pro33Leu), gnomAD 16-53810192-C-T, REVEL 0.52, MetaLR 0.61
- P33P (p.Pro33Pro), rs116753298, gnomAD 16-53810193-C-T, CADD 10.40
- K34E (p.Lys34Glu), gnomAD 16-53810194-A-G, REVEL 0.14, MetaLR 0.18
- D35N (p.Asp35Asn), TOPMed rs2078484206, REVEL 0.60, CADD 28.10
- D35M (p.Asp35Met), gnomAD 16-53810188-AC-A, CADD 26.20
- D36E (p.Asp36Glu), gnomAD rs7499606, REVEL 0.22, CADD 21.50
- D36G (p.Asp36Gly), NCI-TCGA TCGA novel, REVEL 0.41, CADD 22.80, Variant assessed as somatic; moderate impact.
- D36V (p.Asp36Val), TOPMed rs1231833034
- D36N (p.Asp36Asn), gnomAD 16-53810200-G-A, REVEL 0.33, MetaLR 0.41
- E37* (p.Glu37Ter), ExAC rs756946176, gnomAD rs756946176, CADD 41.00
- E37A (p.Glu37Ala), NCI-TCGA Cosmic COSV6711, cosmic curated COSV67111, Variant assessed as somatic; moderate impact.
- F38L (p.Phe38Leu), rs780803760, NCI-TCGA Cosmic COSV1011, cosmic curated COSV10115, ExAC rs780803760, REVEL 0.71, CADD 23.90, Variant assessed as somatic; moderate impact.
- F38F (p.Phe38Phe), rs780803760, gnomAD 16-53810208-C-T, CADD 9.96
- Y39C (p.Tyr39Cys), rs769612021, ClinGen CA8058290, ClinVar RCV002678452, ExAC rs769612021, REVEL 0.47, CADD 24.00, Uncertain significance, Inborn genetic diseases
- Q40K (p.Gln40Lys), gnomAD 16-53810212-C-A, REVEL 0.35, MetaLR 0.43
- Q40Q (p.Gln40Gln), rs1188745184, gnomAD 16-53810214-G-A, CADD 7.24
- Q41H (p.Gln41His), NCI-TCGA Cosmic COSV6711, cosmic curated COSV67114, Variant assessed as somatic; moderate impact.
- Q41K (p.Gln41Lys), gnomAD 16-53810215-C-A, REVEL 0.21, MetaLR 0.26
- Q41* (p.Gln41Ter), gnomAD 16-53810215-C-T, CADD 47.00
- Q41R (p.Gln41Arg), gnomAD 16-53810216-A-G, REVEL 0.33, MetaLR 0.29
- W42* (p.Trp42Ter), ExAC rs768675500, TOPMed rs768675500, gnomAD rs768675500, CADD 48.00
- W42C (p.Trp42Cys), ExAC rs768675500, TOPMed rs768675500, gnomAD rs768675500, REVEL 0.71, CADD 31.00
- Q43H (p.Gln43His), ExAC rs778691805, TOPMed rs778691805, gnomAD rs778691805, REVEL 0.17, CADD 15.80, Uncertain significance, Inborn genetic diseases
- L44M (p.Leu44Met), ExAC rs748048648, TOPMed rs748048648, gnomAD rs748048648, Likely benign
- L44R (p.Leu44Arg), ExAC rs773359111, gnomAD rs773359111, REVEL 0.31, CADD 23.50
- L44V (p.Leu44Val), ExAC rs748048648, TOPMed rs748048648, gnomAD rs748048648, REVEL 0.12, CADD 21.10, Likely benign
- L44L (p.Leu44Leu), rs748048648, gnomAD 16-53825870-C-T, CADD 11.90
- K45E (p.Lys45Glu), ExAC rs771274827, gnomAD rs771274827, REVEL 0.21, CADD 23.00
- K45K (p.Lys45Lys), rs777095923, gnomAD 16-53825875-A-G, CADD 11.20
- Y46N (p.Tyr46Asn), gnomAD 16-53825876-T-A, REVEL 0.88, CADD 28.60
- Y46Y (p.Tyr46Tyr), rs1259855304, gnomAD 16-53825878-T-C, CADD 1.20
- P47R (p.Pro47Arg), TOPMed rs1288155645, REVEL 0.29, CADD 24.10
- P47S (p.Pro47Ser), ExAC rs759800072, gnomAD rs759800072, REVEL 0.18, CADD 18.30
- K48Q (p.Lys48Gln), rs765590518, ClinGen CA8058319, ClinVar RCV001121156, ExAC rs765590518, REVEL 0.45, CADD 24.60, Uncertain significance, Lethal polymalformative syndrome, Boissel type
- K48N (p.Lys48Asn), gnomAD 16-53825884-A-C, REVEL 0.24, CADD 15.00
- L49L (p.Leu49Leu), rs753178443, gnomAD 16-53825885-C-T, CADD 8.52
- I50L (p.Ile50Leu), cosmic curated COSV67112, ESP rs148579300, TOPMed rs148579300, gnomAD rs148579300, REVEL 0.17, CADD 3.43
- L51F (p.Leu51Phe), ESP rs371489995, ExAC rs371489995, TOPMed rs371489995, gnomAD rs371489995, REVEL 0.10, CADD 17.10, Uncertain significance
- L51I (p.Leu51Ile), rs371489995, ClinGen CA8058321, cosmic curated COSV67110, ClinVar RCV002688990, REVEL 0.28, CADD 23.20, Uncertain significance, Inborn genetic diseases
- R52* (p.Arg52Ter), rs531215275, ClinGen CA396121270, NCI-TCGA Cosmic COSV6711, cosmic curated COSV67113, CADD 36.00, Uncertain significance
- R52Q (p.Arg52Gln), cosmic curated COSV10114, ExAC rs755828209, TOPMed rs755828209, gnomAD rs755828209, REVEL 0.37, CADD 24.60, Uncertain significance, Inborn genetic diseases
- R52R (p.Arg52Arg), rs531215275, gnomAD 16-53825894-C-A, CADD 13.00
- E53K (p.Glu53Lys), Ensembl rs2078992599, REVEL 0.26, CADD 23.30
- E53Q (p.Glu53Gln), Ensembl rs2078992599
- A54G (p.Ala54Gly), gnomAD 16-53825901-C-G, REVEL 0.36, CADD 23.50
- S56R (p.Ser56Arg), ExAC rs779539101, TOPMed rs779539101, gnomAD rs779539101, REVEL 0.20, CADD 14.10
- S56N (p.Ser56Asn), gnomAD 16-53825907-G-A, REVEL 0.19, CADD 18.70
- S56S (p.Ser56Ser), rs779539101, gnomAD 16-53825908-T-C, CADD 7.76
- V57I (p.Val57Ile), Ensembl rs2078992796
- V57V (p.Val57Val), gnomAD 16-53825911-A-C, CADD 0.27
- S58Y (p.Ser58Tyr), Ensembl rs1567332084, REVEL 0.33, CADD 23.20
- S58S (p.Ser58Ser), rs146056278, gnomAD 16-53825914-T-C, CADD 0.45
- E60D (p.Glu60Asp), ExAC rs753714090, gnomAD rs753714090
- E60K (p.Glu60Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E60E (p.Glu60Glu), rs753714090, gnomAD 16-53825920-G-A, CADD 5.37
- L61L (p.Leu61Leu), gnomAD 16-53825923-C-G, CADD 4.39
- H62R (p.His62Arg), rs550932456, ClinGen CA8058327, ClinVar RCV001866848, ClinVar RCV003136206, REVEL 0.87, CADD 23.60, Uncertain significance, not provided; Lethal polymalformative syndrome, Boissel type
- H62P (p.His62Pro), gnomAD 16-53825925-A-C, REVEL 0.86, CADD 24.30
- K63E (p.Lys63Glu), TOPMed rs2078993270, REVEL 0.20, CADD 15.60
- K63N (p.Lys63Asn), rs964883898, ClinGen CA396121351, ClinVar RCV003013997, Uncertain significance, not provided
- K63K (p.Lys63Lys), rs964883898, gnomAD 16-53825929-A-G, CADD 1.55
- E64G (p.Glu64Gly), ExAC rs778727414, REVEL 0.24, CADD 23.80
- V65F (p.Val65Phe), gnomAD rs1304763607, REVEL 0.79, CADD 25.60
- V65I (p.Val65Ile), gnomAD rs1304763607, REVEL 0.42, CADD 23.30
- V65V (p.Val65Val), rs1403403281, gnomAD 16-53825935-T-G, CADD 1.61
- Q66H (p.Gln66His), gnomAD rs1414523806, REVEL 0.56, CADD 14.90
- Q66* (p.Gln66Ter), gnomAD 16-53825936-C-T, CADD 35.00
- Q66Q (p.Gln66Gln), rs1414523806, gnomAD 16-53825938-A-G, CADD 1.59
- E67D (p.Glu67Asp), TOPMed rs975320571, gnomAD rs975320571, REVEL 0.07, CADD 9.76
- A68G (p.Ala68Gly), gnomAD rs555319581, REVEL 0.51, CADD 23.40
- A68S (p.Ala68Ser), gnomAD 16-53825942-G-T, REVEL 0.53, CADD 24.10
- A68D (p.Ala68Asp), gnomAD 16-53825943-C-A, REVEL 0.85, CADD 25.00
- A68A (p.Ala68Ala), gnomAD 16-53825944-C-T, CADD 10.40
- F69I (p.Phe69Ile), gnomAD rs1352866890
- F69L (p.Phe69Leu), gnomAD rs1352866890, REVEL 0.53, CADD 24.00
- F69V (p.Phe69Val), gnomAD rs1352866890, REVEL 0.78, CADD 26.00, Uncertain significance, Inborn genetic diseases
- F69F (p.Phe69Phe), gnomAD 16-53825947-T-C, CADD 8.74
Public FTO analysis runs
- FTO analysis run — FTO (820 variants) — completed 2026-08-19